EP1851244A4 - Anticorps anti-cd137 en tant qu'agent dans le traitement de cancers et variante de glycosylation dudit anticorps - Google Patents
Anticorps anti-cd137 en tant qu'agent dans le traitement de cancers et variante de glycosylation dudit anticorpsInfo
- Publication number
- EP1851244A4 EP1851244A4 EP05723079A EP05723079A EP1851244A4 EP 1851244 A4 EP1851244 A4 EP 1851244A4 EP 05723079 A EP05723079 A EP 05723079A EP 05723079 A EP05723079 A EP 05723079A EP 1851244 A4 EP1851244 A4 EP 1851244A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatement
- antibody
- cancer
- agent
- glycosylation variants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11173253A EP2399935A3 (fr) | 2005-02-15 | 2005-02-15 | Anticorps anti- CD137 en tant qu'agent dans le traitement du cancer et variantes de glycosylation correspondantes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2005/004739 WO2006088447A1 (fr) | 2005-02-15 | 2005-02-15 | Anticorps anti-cd137 en tant qu'agent dans le traitement de cancers et variante de glycosylation dudit anticorps |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1851244A1 EP1851244A1 (fr) | 2007-11-07 |
EP1851244A4 true EP1851244A4 (fr) | 2009-04-15 |
Family
ID=36916751
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11173253A Withdrawn EP2399935A3 (fr) | 2005-02-15 | 2005-02-15 | Anticorps anti- CD137 en tant qu'agent dans le traitement du cancer et variantes de glycosylation correspondantes |
EP05723079A Withdrawn EP1851244A4 (fr) | 2005-02-15 | 2005-02-15 | Anticorps anti-cd137 en tant qu'agent dans le traitement de cancers et variante de glycosylation dudit anticorps |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11173253A Withdrawn EP2399935A3 (fr) | 2005-02-15 | 2005-02-15 | Anticorps anti- CD137 en tant qu'agent dans le traitement du cancer et variantes de glycosylation correspondantes |
Country Status (2)
Country | Link |
---|---|
EP (2) | EP2399935A3 (fr) |
WO (1) | WO2006088447A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1945666T3 (da) * | 2005-10-21 | 2013-07-01 | Genzyme Corp | Antistoffer med forøget antistofafhængig cellulær cytotoksicitetsaktivitet, fremgangsmåder til fremstilling af disse og anvendelse heraf |
AU2012201010B2 (en) * | 2005-10-21 | 2015-01-22 | Genzyme Corporation | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
ES2336873B1 (es) * | 2007-11-07 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Composicion farmaceutica para el tratamiento de cancer. |
US20110229460A1 (en) * | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
WO2010042433A1 (fr) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives |
ES2377785B2 (es) | 2010-09-08 | 2012-09-26 | Universidad Miguel Hernández De Elche | Composición farmacéutica para el tratamiento del ojo seco. |
CN105481983B (zh) | 2010-09-09 | 2021-09-03 | 辉瑞公司 | 4-1bb结合分子 |
US20140178368A1 (en) * | 2011-04-19 | 2014-06-26 | Leslie Lynne SHARP | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
KR20160002713A (ko) | 2013-02-13 | 2016-01-08 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도 |
RU2016146993A (ru) * | 2014-05-21 | 2018-06-21 | Пфайзер Инк. | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака |
MX2017010793A (es) | 2015-02-22 | 2018-07-06 | Sorrento Therapeutics Inc | Terapeuticos de anticuerpo que ligan cd137. |
RU2017142008A (ru) | 2015-05-21 | 2019-06-24 | Эллигейтор Биосайенс Аб | Новые полипептиды |
AU2016291817A1 (en) | 2015-07-16 | 2018-02-22 | Biolinerx Ltd. | Compositions and methods for treating cancer |
WO2017049452A1 (fr) * | 2015-09-22 | 2017-03-30 | 苏州丁孚靶点生物技术有限公司 | Anticorps entièrement humain contre cd137 humain et son utilisation |
CN108424928B (zh) | 2016-12-30 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
WO2018121787A1 (fr) * | 2016-12-30 | 2018-07-05 | Beijing Biocytogen Co., Ltd | Animal non humain génétiquement modifié à cd137 humain ou chimérique |
WO2019036855A1 (fr) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Molécules anti-cd137 et leur utilisation |
WO2019148445A1 (fr) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation |
EP3806888B1 (fr) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Constructions régulatrices dérivées de pde5 et procédés d'utilisation en immunothérapie |
CN112867733B (zh) * | 2018-10-19 | 2023-01-06 | 苏州丁孚靶点生物技术有限公司 | 抗cd137抗体及其应用 |
WO2021226883A1 (fr) * | 2020-05-13 | 2021-11-18 | Adagene Ag | Compositions et procédés de traitement du cancer par soumission d'un listage des séquences sur un fichier texte ascii |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998016249A1 (fr) * | 1996-10-11 | 1998-04-23 | Bristol-Myers Squibb Company | Methodes d'immunomodulation et compositions associees |
WO2000029445A1 (fr) * | 1998-11-17 | 2000-05-25 | Lg Chemical Limited | Anticorps humanise specifique a la proteine humaine 4-1bb et composition pharmaceutique le comprenant |
WO2003049755A1 (fr) * | 2001-10-09 | 2003-06-19 | Mayo Foundation For Medical Education And Research | Amelioration des reponses immunitaires par des agents liant 4-1bb |
US20040025193A1 (en) * | 2002-08-01 | 2004-02-05 | Yann Echelard | Method for the rapid selection of homozygous primary cell lines for the production of transgenic animals by somatic cell nuclear transfer |
WO2004010947A2 (fr) * | 2002-07-30 | 2004-02-05 | Bristol-Myers Squibb Company | Anticorps humanises contre le 4-1bb humain |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7414170B2 (en) * | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
-
2005
- 2005-02-15 WO PCT/US2005/004739 patent/WO2006088447A1/fr active Application Filing
- 2005-02-15 EP EP11173253A patent/EP2399935A3/fr not_active Withdrawn
- 2005-02-15 EP EP05723079A patent/EP1851244A4/fr not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998016249A1 (fr) * | 1996-10-11 | 1998-04-23 | Bristol-Myers Squibb Company | Methodes d'immunomodulation et compositions associees |
WO2000029445A1 (fr) * | 1998-11-17 | 2000-05-25 | Lg Chemical Limited | Anticorps humanise specifique a la proteine humaine 4-1bb et composition pharmaceutique le comprenant |
WO2003049755A1 (fr) * | 2001-10-09 | 2003-06-19 | Mayo Foundation For Medical Education And Research | Amelioration des reponses immunitaires par des agents liant 4-1bb |
WO2004010947A2 (fr) * | 2002-07-30 | 2004-02-05 | Bristol-Myers Squibb Company | Anticorps humanises contre le 4-1bb humain |
US20040025193A1 (en) * | 2002-08-01 | 2004-02-05 | Yann Echelard | Method for the rapid selection of homozygous primary cell lines for the production of transgenic animals by somatic cell nuclear transfer |
Non-Patent Citations (11)
Title |
---|
HORAN-HAND P ET AL: "COMPARATIVE BIOLOGICAL PROPERTIES OF A RECOMBINANT CHIMERIC ANTI-CARCINOMA MAB AND A RECOMBINANT AGLYCOSYLATED VARIANT", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 35, no. 3, 1992, pages 165 - 174, XP001539281, ISSN: 0340-7004 * |
HUMPHREYS D P ET AL: "THERAPEUTIC ANTIBODY PRODUCTION TECHNOLOGIES: MOLECULES, APPLICATIONS, EXPRESSION AND PURIFICATION", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 4, no. 2, 1 March 2001 (2001-03-01), pages 172 - 185, XP008016086, ISSN: 1367-6733 * |
MEADE H M ET AL: "Expression of recombinant proteins in the milk of transgenic animals", GENE EXPRESSION SYSTEMS. USING NATURE FOR THE ART OF EXPRESSION, XX, XX, 1 January 1999 (1999-01-01), pages 399 - 427, XP009088286 * |
OKAZAKI A ET AL: "Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcgammaRIIIa", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 336, no. 5, 5 March 2004 (2004-03-05), pages 1239 - 1249, XP004490178, ISSN: 0022-2836 * |
POLLOCK D P ET AL: "Transgenic milk as a method for the production of recombinant antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 147 - 157, XP004186081, ISSN: 0022-1759 * |
See also references of WO2006088447A1 * |
SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC., BALTIMORE, MD, US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002495886, ISSN: 0021-9258, [retrieved on 20001128], DOI: 10.1074/JBC.M009483200 * |
SHIELDS ROBERT L ET AL: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 30, 26 July 2002 (2002-07-26), pages 26733 - 26740, XP002442140, ISSN: 0021-9258 * |
W. LIN ET AL: "Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies", BLOOD, vol. 112, no. 3, 1 August 2008 (2008-08-01), pages 699 - 707, XP055037053, ISSN: 0006-4971, DOI: 10.1182/blood-2007-11-122465 * |
WRIGHT A ET AL: "EFFECT OF ALTERED CH2-ASSOCIATED CARBOHYDRATE STRUCTURE ON THE FUNCTIONAL PROPERTIES AND IN VIVO FATE OF CHIMERIC MOUSE-HUMAN IMMUNOGLOBULIN G1", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 180, no. 3, 1 September 1994 (1994-09-01), pages 1087 - 1096, XP000676306, ISSN: 0022-1007 * |
ZHOU Q ET AL: "Effect of genetic background on glycosylation heterogeneity in human antithrombin produced in the mammary gland of transgenic goats", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 117, no. 1, 20 April 2005 (2005-04-20), pages 57 - 72, XP004836787, ISSN: 0168-1656 * |
Also Published As
Publication number | Publication date |
---|---|
EP2399935A3 (fr) | 2012-02-22 |
WO2006088447A1 (fr) | 2006-08-24 |
EP1851244A1 (fr) | 2007-11-07 |
EP2399935A2 (fr) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1851244A4 (fr) | Anticorps anti-cd137 en tant qu'agent dans le traitement de cancers et variante de glycosylation dudit anticorps | |
HUS1700015I1 (hu) | PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél | |
IL178012A0 (en) | Diphenyl-indol-2-on compounds and their use in the treatment of cancer | |
HRP20140271T1 (hr) | Humana antitijela protiv bjesnoä†e i njihova uporaba | |
IL184659A0 (en) | Antibody variants and uses thereof | |
GB0509738D0 (en) | Processor and interface | |
IL187503A0 (en) | Stable and soluble antibodies | |
EP1746884A4 (fr) | Préparations de hyaluronane stabilisé et méthodes correspondantes | |
EP1968649A4 (fr) | Nanoparticules de proteines et leur utilisation | |
EP1747284A4 (fr) | Diagnostics et therapeutiques du cancer | |
IL188031A0 (en) | Use of thiazole derivatives and analogues in the treatment of cancer | |
HK1215683A1 (zh) | 抗葉酸藥在癌症治療中的聯合應用 | |
EP1874800A4 (fr) | Agents diagnostiques et thérapeutiques | |
IL181608A0 (en) | Cancer combination therapy comprising azd2171 and imatinib | |
IL180278A0 (en) | Fused pyrimidones useful in the treatment and the prevention of cancer | |
EP1841467A4 (fr) | Therapie du cancer de combinaison avec des anticorps diriges contre l'antigene membranaire specifique de la prostate | |
EP2123266A4 (fr) | Agent thérapeutique contre le cancer et agent anti-carcinogène | |
ZA200800243B (en) | Use of thiazole derivatives and analogues in the treatment of cancer | |
IL181300A0 (en) | Photosensitizer formulations and uses thereof | |
ZA200709542B (en) | Combination therapy in the treatment of cancer | |
EP1904088A4 (fr) | Compositions et methodes de traitement du cancer | |
EP1786415A4 (fr) | Agents de modulation du métabolisme et utilisations associées | |
IL185575A0 (en) | Benzoxazocines and their therapeutic use | |
GB0520935D0 (en) | Integrated processor-template-system and project | |
GB2448627B (en) | Combination therapy and antibody panels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070910 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090317 |
|
17Q | First examination report despatched |
Effective date: 20090629 |
|
DAC | Divisional application: reference to earlier application (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130319 |